
Commentary|Videos|December 8, 2025
Dr Patel on the Efficacy of Anitocabtagene Autoleucel in R/R Multiple Myeloma
Author(s)Krina K. Patel, MD, MSc
Fact checked by: Ashling Wahner , Chris Ryan
Krina K. Patel, MD, MSc, discusses the efficacy of anitocabtagene autoleucel in relapsed/refractory multiple myeloma from the iMMagine-1 trial.
Advertisement
“The biggest update is that the overall response rate is still 96%, and then [regarding] depth of response, the complete response [CR]/stringent CR rate is 74%. [We have] big minimal residual disease [MRD] data on the majority of our patients now. [In total], 95% of patients were MRD undetectable at [a sensitivity of] 10–5.”
Krina K. Patel, MD, MSc, an associate professor in the Department of Lymphoma/Myeloma in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discussed findings from the phase 2 iMMagine-1 trial (NCT05396885) investigating anitocabtagene autoleucel in patients with relapsed/refractory multiple myeloma.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
3
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5






































